Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), today issued a corporate update. Among other items highlighted in the update, the Company continues to work with the British Columbia Securities Commission (the “Commission”) to complete its continuous disclosure review. Champignon Brands will continue to fully cooperate with the Commission to assist in completion of the … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Issues Corporate Update”
Disseminated on behalf of Helus Pharma Inc., may include paid advertisements. Investment Considerations HLP003 is in Phase 3 development with FDA Breakthrough Therapy Designation for adjunctive treatment of major depressive disorder. Twelve-month data following two 16 mg doses demonstrated sustained improvements in depression symptoms, including 100% responder and 71% remission rates in the analyzed cohort. … Continue reading “Helus Pharma Inc. (NASDAQ: HELP) (NEO: HELP)”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced that it has been selected for a continuous disclosure review by the British Columbia Securities Commission (the “Commission”). The review relates to Champignon’s disclosure obligations since it became a reporting issuer on … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Regulatory Review”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, continues to highlight the scientific merit of its ketamine treatments for Major Depressive Disorder (“MDD”) while demonstrating rapid onset efficacy and safety of its treatment processes. To this accord, the Company today announced that … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc.’s (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Dr. McIntyre / CRTCE Published in Two Peer Reviewed Study Journals”
Pure Extracts is the development leader in the Canadian cannabis extract segment, which is valued by Deloitte at $2.7 billion annually. The Company is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products. The psychedelic and functional mushroom industries are among the … Continue reading “Pure Extracts Corp. is “One to Watch””
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, on Friday provided a corporate update. Since commencing trading on March 2, 2020, the Company has expanded its initiatives and rapidly executed on such initiatives to position it as a leading publicly traded psychedelic … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Provides Corporate Update”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced its selection of Toronto-based Dalriada Drug Discovery Inc. (“Dalriada”) to advance its new chemical entity (“NCE”) IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds. According to the update, Dalriada, … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Engages Toronto-based Dalriada to Advance NCE IP Portfolio”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human-optimization sciences company with an emphasis on ketamine and psychedelic medicine, recently named Dr. Roger McIntyre as chief executive officer. An article discussing the company reads, “In his new role, Dr. Roger McIntyre brings impressive experience in the ketamine and psychedelic medicine space, a key focus … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Names New CEO”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, today announced that certain shareholders have agreed to a voluntary resale restriction period covering 17,840,000 common shares extending the period of time before the shares become free trading to July 15, 2020. According to … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Voluntary Share Lock-Up, Engagement of Gold Standard Media for Marketing and Consulting Services”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company with an emphasis on ketamine and psychedelic medicine, on Monday announced the appointment of Dr. Bill Wilkerson, LL.D. (Hon), an 8-time award-winning pioneer in workplace mental health, to its board of directors. In addition, the company reported the resignation of Mr. Joe … Continue reading “QualityStocksNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Appoints New Member to Board of Directors”
